Ourotech helps pharma companies determine the best drug candidates in their lead/preclinical pipeline to reduce false positives early. Ourotech creates proprietary reagents that can be used for engineering predictive, high drug resistance tumor models. Ourotech’s first product, Genesis, can be used to mimic the mechanical properties and pH and oxygen gradients of solid in-vivo tumors to supplement the flaws of mice models.